This site is intended for U.S. healthcare professionals only.

Dosing & Administration

Ensacove™ offers convenient once-daily dosing and no food restrictions.1

Convenient Once-Daily Oral Dosing

  • Once daily dosing
  • 225 mg taken as 3 capsules (available in 100 mg and 25 mg strengths)
No food restrictions
Can be taken with or without food1

NCCN, National Comprehensive Cancer Network; 1L, first line; ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer.

Efficacy Data

Ensacove™ (ensartinib) is a second generation ALK TKI approved by the FDA for ALK+ NSCLC in patients who have not previously received an ALK-inhibitor.1

View eXalt3 Results

Established Safety

Established safety profile over a median follow up of 74 months.1,3

Learn More